Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based ...
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) is a clinical-stage biopharmaceutical company formed in May 2020 and based in New Jersey. The company’s core business centers on advancing a single, flagship therapeutic platform—Apitox—through the research, development, production, and commercialization lifecycle typical of early-stage drug developers. Apitox is described as an ...Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) is a clinical-stage biopharmaceutical company formed in May 2020 and based in New Jersey. The company’s core business centers on advancing a single, flagship therapeutic platform—Apitox—through the research, development, production, and commercialization lifecycle typical of early-stage drug developers. Apitox is described as an intradermally administered, bee-venom-based active pharmaceutical ingredient. The therapeutic intent is to help manage inflammation and pain symptoms associated with osteoarthritis and multiple sclerosis, positioning the product development effort within the broader inflammation/pain and neurology/orthopedics markets.
From a product and development perspective, APUS is primarily in a “build-and-advance” mode rather than a revenue-producing, mass-commercial manufacturing stage. For a clinical-stage biopharma, major operational cost drivers generally include clinical trial execution (site selection, patient enrollment, monitoring, and compliance), regulatory and documentation support, manufacturing development and supply chain setup for investigational material, and quality systems needed for pharmaceutical-grade inputs. While specific line-item cost breakdowns and bill-of-materials (BOM) details for Apitox are not provided in the supplied data, bee-venom-based products typically require sourcing and processing of biological inputs, controlled formulation work, and stringent testing to support stability, potency, and safety requirements.
Financially, the company’s market metrics in the provided information show a relatively small market capitalization and negative profitability signals consistent with early-stage development companies. Provided TTM indicators include negative operating return on assets and negative free cash flow yield, alongside working-capital and invested-capital figures that appear negative in the snapshot. These patterns are common for companies still funding development and ramping capabilities.
Key people include Vinod Menon (Chief Executive Officer and Director). Additional listed leadership roles include Erik Emerson (President and Director) and Christopher M. H. Kim, MD (Chief Medical Officer), along with an executive team that includes a CFO. As APUS progresses, expected “next steps” for value creation are typically advancement of clinical development milestones, progress toward regulatory approvals, scaling and qualification of manufacturing processes, and establishing a path to commercialization.
Overall, APUS’s strategy is to move Apitox from investigational development toward later-stage clinical outcomes and, ultimately, therapeutic adoption, leveraging its focus on a targeted mechanism aimed at reducing inflammation and pain symptoms in specific patient populations.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-6.0M
-331.7%
+42.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-9.0M
-1124.6%
-187.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
5.1%
+111.5%
+81.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.31x
+10146.6%
-43.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
